The Pfizer is inviting applications for its competitive grant program focused on enhancing medical education related to emerging treatments in metastatic castration-resistant prostate cancer (mCRPC). This initiative prioritizes activities that address new mechanisms of action, such as EZH2 inhibition, and the critical unmet need for innovative therapies beyond traditional chemotherapy. Grants ranging from $75,000 to […]
Access Restricted: Members-Only Content. We're sorry, but this content is available exclusively to our subscribed members: